{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:17:03Z","timestamp":1791335823996,"version":"4.3.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sophien Foundation"},{"name":"Stiftung f\u00fcr angewandte Krebsforschung"},{"name":"Promedica Foundation"},{"name":"University Hospital Zurich Cancer Center"},{"name":"National Cancer Institute Cancer Center Core","award":["P30-CA008748"],"award-info":[{"award-number":["P30-CA008748"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There are no validated tools for the clinical neurological assessment of patients with leptomeningeal metastases (LM). However, clinical examination during the course of the disease guides medical management and is part of response assessment in clinical trials. Because neuroimaging may not always be obtained owing to rapid clinical deterioration, clinical neurological assessment of LM is essential, and standardization is important to minimize rater disagreement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Response Assessment in Neuro-oncology-LM group launched a 2-step process, aiming at improving and standardizing the clinical assessment of patients with LM. We report here on the first step the establishment of a consensus scorecard. The task force had 9 virtual meetings to define general recommendations on neurological assessment and selected domains of interest that should be tested.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fourteen domains of neurological symptoms and signs were selected: level of consciousness, cognition, nausea and vomiting, vision, eye movement, facial strength, hearing, swallowing, speech, limb strength, limb ataxia, walking, and bladder bowel functions. For each item, a clear instruction on how to perform the assessment is provided with scoring criteria between 0 and 2. The general clinical status of the patient and use of steroids, pain medications, and antiemetics should be documented. Neurological sequelae from previous brain metastases or cancer treatment should be rated at the baseline evaluation; it should be specified when symptoms or signs may be related to a condition other than LM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>A revised Neurological Assessment in Neuro-Oncology-LM consensus scorecard for clinical assessment has been established. An international prospective validation study of the proposal is currently ongoing (NCT06417710).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noae171","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T11:33:44Z","timestamp":1724758424000},"page":"455-465","source":"Crossref","is-referenced-by-count":12,"title":["NANO-LM: An updated scorecard for the clinical assessment of patients with leptomeningeal metastases"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9408-3278","authenticated-orcid":false,"given":"Emilie","family":"Le Rhun","sequence":"first","affiliation":[{"name":"Departments of Neurology and Neurosurgery, Clinical Neuroscience Center, University Hospital and University of Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Nayak","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber Cancer Institute , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jane","family":"Lim-Fat","sequence":"additional","affiliation":[{"name":"Division of Neurology, Sunnybrook Health Sciences Centre, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Rud\u00e0","sequence":"additional","affiliation":[{"name":"Division of Neuro-Oncology, Department of Neuroscience, University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5854-0251","authenticated-orcid":false,"given":"Elena","family":"Pentsova","sequence":"additional","affiliation":[{"name":"Department of Neurology, Brain Tumor Service, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3756-8594","authenticated-orcid":false,"given":"Peter","family":"Forsyth","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute , Tampa, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara J","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center Department of Neuro-Oncology, , Houston, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3541-2315","authenticated-orcid":false,"given":"Matthias","family":"Preusser","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine 1, Medical University of Vienna , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5923-0677","authenticated-orcid":false,"given":"Priya","family":"Kumthekar","sequence":"additional","affiliation":[{"name":"The Lou and Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7998-9904","authenticated-orcid":false,"given":"Dieta","family":"Brandsma","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, Netherlands Cancer Institute , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-174X","authenticated-orcid":false,"given":"Michael","family":"Weller","sequence":"additional","affiliation":[{"name":"Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"issue":"5","key":"2025021114225252100_CIT0001","doi-asserted-by":"crossref","first-page":"101624","DOI":"10.1016\/j.esmoop.2023.101624","article-title":"Leptomeningeal metastasis from solid tumours: EANO-ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"8","author":"Le Rhun","year":"2023","journal-title":"ESMO Open"},{"key":"2025021114225252100_CIT0002","volume-title":"NCCN Clinical Practice Guidelines in Oncology_Central Nervous System Cancers_Version 1.2023","year":"2023"},{"key":"2025021114225252100_CIT0003","first-page":"noae103","article-title":"Leptomeningeal metastases from solid tumors: a SNO and ASCO consensus review on clinical management and future directions","volume-title":"Neuro-Oncol","author":"Wilcox","year":"2024"},{"issue":"2","key":"2025021114225252100_CIT0004","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/neuonc\/noac180","article-title":"Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis","volume":"25","author":"Oberkampf","year":"2023","journal-title":"Neuro Oncol"},{"issue":"3","key":"2025021114225252100_CIT0005","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/neuonc\/noac195","article-title":"A phase I\/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: safety, efficacy, and cerebrospinal fluid pharmacokinetics","volume":"25","author":"Kumthekar","year":"2023","journal-title":"Neuro Oncol"},{"issue":"4","key":"2025021114225252100_CIT0006","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41591-022-02170-x","article-title":"Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results","volume":"29","author":"Glitza Oliva","year":"2023","journal-title":"Nat Med."},{"issue":"4","key":"2025021114225252100_CIT0007","doi-asserted-by":"crossref","first-page":"102384","DOI":"10.1016\/j.esmoop.2024.102384","article-title":"Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trial","volume":"9","author":"Fan","year":"2024","journal-title":"ESMO Open"},{"issue":"8","key":"2025021114225252100_CIT0008","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-020-0918-0","article-title":"Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis","volume":"26","author":"Brastianos","year":"2020","journal-title":"Nat Med."},{"issue":"8","key":"2025021114225252100_CIT0009","doi-asserted-by":"crossref","first-page":"e002473","DOI":"10.1136\/jitc-2021-002473","article-title":"Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers","volume":"9","author":"Naidoo","year":"2021","journal-title":"J Immunother Cancer."},{"issue":"Suppl_3","key":"2025021114225252100_CIT0010","first-page":"iii14","article-title":"Lmap-21 preliminary clinical data in the phase 1\/2a dose escalation trial of rhenium (186re) Obisbemeda (186rnl) in leptomeningeal metastases (LM): the respect-Lm trial","volume":"5","author":"Youssef","year":"2023","journal-title":"Neurooncol Adv."},{"issue":"20","key":"2025021114225252100_CIT0011","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1158\/1078-0432.CCR-20-1764","article-title":"A phase 2 study of abemaciclib in patients with brain metastases secondary to hormone receptor positive breast cancer","volume":"26","author":"Tolaney","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"10","key":"2025021114225252100_CIT0012","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.annonc.2020.06.017","article-title":"A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy","volume":"31","author":"Park","year":"2020","journal-title":"Ann Oncol."},{"issue":"4","key":"2025021114225252100_CIT0013","first-page":"484","article-title":"Leptomeningeal metastases: a RANO proposal for response criteria","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro Oncol."},{"issue":"9","key":"2025021114225252100_CIT0014","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/neuonc\/nou089","article-title":"Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials","volume":"16","author":"Chamberlain","year":"2014","journal-title":"Neuro Oncol."},{"issue":"10","key":"2025021114225252100_CIT0015","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/neuonc\/noac043","article-title":"Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: a joint EORTC BTG and RANO effort","volume":"24","author":"Le Rhun","year":"2022","journal-title":"Neuro Oncol"},{"issue":"7","key":"2025021114225252100_CIT0016","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/neuonc\/noaa298","article-title":"Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors","volume":"23","author":"Le Rhun","year":"2021","journal-title":"Neuro Oncol"},{"issue":"5","key":"2025021114225252100_CIT0017","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/neuonc\/nox029","article-title":"The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria","volume":"19","author":"Nayak","year":"2017","journal-title":"Neuro Oncol."},{"issue":"11","key":"2025021114225252100_CIT0018","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology."},{"issue":"1\u20132","key":"2025021114225252100_CIT0019","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","article-title":"The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function","volume":"169","author":"Cedarbaum","year":"1999","journal-title":"J Neurol Sci."},{"key":"2025021114225252100_CIT0020","doi-asserted-by":"publisher","DOI":"10.1002\/9781118445112.stat06823","article-title":"National Institutes of Health Stroke Scale (NIHSS)","volume-title":"Wiley StatsRef: Statistics Reference Online","author":"Ortiz","year":"2014","edition":"1"},{"issue":"1","key":"2025021114225252100_CIT0021","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1477-7525-1-54","volume":"1","author":"Horsman","year":"2003","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"2025021114225252100_CIT0022","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0895-4356(89)90065-6","article-title":"Improving the sensitivity of the Barthel Index for stroke rehabilitation","volume":"42","author":"Shah","year":"1989","journal-title":"J Clin Epidemiol."},{"issue":"5","key":"2025021114225252100_CIT0023","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/neuonc\/noz024","article-title":"The RANO leptomeningeal metastasis group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal","volume":"21","author":"Le Rhun","year":"2019","journal-title":"Neuro Oncol"},{"issue":"1","key":"2025021114225252100_CIT0024","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics."},{"issue":"5","key":"2025021114225252100_CIT0025","first-page":"360","article-title":"Understanding interobserver agreement: the kappa statistic","volume":"37","author":"Viera","year":"2005","journal-title":"Fam Med."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noae171\/59835697\/noae171.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/27\/2\/455\/59835697\/noae171.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/27\/2\/455\/59835697\/noae171.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T09:23:14Z","timestamp":1739265794000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/27\/2\/455\/7745349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,8,29]]},"published-print":{"date-parts":[[2025,2,10]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noae171","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,8,29]]}}}